a public good project by the
Synthesis
Company
of California

© 2026

Kevin J. Harrington | doi.page

0 works0 citations0 h-index

Kevin J. Harrington

Publications by Year

Research Areas

Head and Neck Cancer Studies, Virus-based gene therapy research, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Cancer Research and Treatments

Most-Cited Works

→ Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck(2016)4,969 cited
→ Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study(2019)3,089 cited
→ Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma(2015)2,541 cited
→ The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence(2015)2,081 cited
→ Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial(2011)1,665 cited
→ Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study(2018)1,656 cited

→ Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells(2007)1,544 cited

→ Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts(2013)1,387 cited

→ Consensus guidelines for the definition, detection and interpretation of immunogenic cell death(2020)1,014 cited

→ Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial(2018)1,004 cited